befunolol has been researched along with betaxolol in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Altafini, R; Cerin, O; Dorigo, MT; Fracasso, G | 1 |
Eckerskorn, U; Ermisch, S; Fournes, C; Hockwin, O; Möller, B; Müller, P; Wegener, A | 1 |
Arrico, L; Collini, S; Grechi, G; Pecori-Giraldi, J; Planner-Terzaghi, A | 1 |
Braakman, R; Sipkema, P; van der Linden, P | 1 |
Iga, T; Ito, K; Ohtani, H; Sawada, Y; Takayanagi, R; Tsuchiya, K; Yamada, Y | 1 |
2 trial(s) available for befunolol and betaxolol
Article | Year |
---|---|
Cardiovascular effects of befunolol, betaxolol and timolol eye drops.
Topics: Adrenergic beta-Antagonists; Betaxolol; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Glaucoma; Heart Rate; Humans; Male; Middle Aged; Propanolamines; Timolol | 1990 |
[Timolol, betaxolol and befunolol in the treatment of glaucoma. Study of their bronchopulmonary effects].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Clinical Trials as Topic; Female; Forced Expiratory Volume; Glaucoma, Open-Angle; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Propanolamines; Random Allocation; Timolol; Vital Capacity | 1988 |
3 other study(ies) available for befunolol and betaxolol
Article | Year |
---|---|
[Effects of 3 topically administered beta blockers on the rabbit crystalline lens].
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Lens, Crystalline; Ophthalmic Solutions; Propanolamines; Rabbits; Timolol | 1988 |
Effects of topical beta-blockers on the diameter of the isolated porcine short posterior ciliary artery.
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Ciliary Arteries; Ciliary Body; Hemodynamics; Muscle, Smooth, Vascular; Ophthalmic Solutions; Pressure; Propanolamines; Swine; Timolol; Vasodilation | 1999 |
Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Cardiovascular Diseases; Carteolol; Exercise; Forced Expiratory Volume; Heart; Heart Rate; Humans; Lung; Ophthalmic Solutions; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Respiration Disorders; Retrospective Studies; Timolol | 2001 |